5th surfactant (lucinactant) for respiratory distress syndrome (RDS) in premature infants approved by the FDA today
The fifth surfactant to be approved to treat Respiratry Distress Syndrome (RDS) was approved by the FDA today. the new drug is called Surfaxin (lucinactant) and joins the 4 previously approved medicines for RDS. This drug was approved to prevent RDS based on one study of 1,294 premature infants. read the release at www.fda.gov.